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Abstract
This article presents a general analysis of contemporary data on the correlation between polycystic ovarian syndrome (SOPC) and neurological 
diseases.  The most frequent neurological disorder associated with SOPC is epilepsy, which is a serious health problem.  Data show a higher 
frequency of SOPC in women suffering from epilepsy, and some of the authors link this phenomenon to the adverse effects of treatments with 
valproic acid.  Other the neurological diseases associated with SOPC also include non-convulsive disorders.
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Неврологические нарушения при синдроме поликистозных яичников 
Дан анализ современных представлений о взаимосвязи синдрома поликистозных яичников (СПКЯ) и патологий нервной системы. 
Частота сочетания СПКЯ и неврологических нарушений представлена, в первую очередь, эпилепсией при СПКЯ, что является 
актуальной медицинской проблемой.  Имеются данные о повышении частоты СПКЯ у женщин больных эпилепсией, причем ряд 
авторов связывают этот феномен с применением препаратов вальпроевой кислоты.  Среди неврологических патологий, сочетающихся 
с СПКЯ, встречаются также и бессудорожные нарушения.
Ключевые слова: синдром поликистозных яичников, эпилепсия, неврологические нарушения.
Introduction
Polycystic ovarian syndrome (PCOS) was originally 
reported by Stein and Leventhal in 1935 when they studied 
a group of women suffering from amenorrhea, infertilty, en-
larged polycystic ovaries and hirsutism.  Most women who 
suffer from this condition experience infrequent or irregular 
menstrual cycles.
Polycystic ovary syndrome is an endocrine disorder that 
affects between 5% and 15% of all women of reproductive 
age [1].  It occurs among all races and nationalities, and is a 
leading cause in 73% of women with anovulatory infertility [2, 
3].  The majority of specialists consider PCOS a heterogenous 
pathology, whose principle features are obesity, anovulation, 
acne and excessive amounts or effects of androgenic hormo-
nes.  The symptoms and severity of the syndrome vary greatly 
among women.  Insulin resistance, diabetes and obesity are 
all strongly correlated with PCOS, although the causes are 
still disputable. 
Other names for this syndrome include polycystic ova-
ry disease (PCOD), functional ovarian hyperandrogenism, 
Stein-Leventhal syndrome (original name, not widely used 
in modern literature), ovarian hyperthecosis and sclerocystic 
ovary syndrome.
Common symptoms of PCOS include:
	Oligomenorrhea, amenorrhea
	Infertility
	Hirsutism
	Hair loss
	Acne vulgaris
	Seborrhoeic dermatitis
	Obesity or weight gain
	Deepening of voice
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Mild symptoms of hyperandrogenism, such as acne or 
hyperseborrhea, are frequent in adolescent girls and are often 
associated with irregular menstrual cycles.  In most instances, 
these symptoms are transient and only reflect the immaturity 
of the hypothalamic-pituitary-ovarian axis during the first 
years following menarche [4].
The heterogeneity in the signs and symptoms of PCOS 
has led to considerable controversy in this area due to the 
difficulty in establishing a uniformly accepted definition 
of PCOS.  What is clear, however, is that women with the 
disorder do not ovulate in a predictable manner and women 
with PCOS also produce excessive quantities of androgens 
(particularly testosterone).  Polycystic ovaries are not present 
in all women diagnosed with PCOS.  Also, many women with 
regular menstrual periods and normal levels of testosterone 
have cystic ovaries.
Two definitions are commonly used to describe the 
pathology:
1) The National Institutes of Health (NIH 1990) criteria 
for PCOS require both:
a) the presence of ovulatory dysfunction; 
b) clinical and/or biochemical evidence of hyperandro-
genism with exclusion of other endocrinopathies [5].
2) The revised European Society of Human Reproduc-
tion and Embryology (Rotterdam 2003) criteria for PCOS 
require 2 out of 3 symptoms mentioned below:
a) oligoovulation and/or anovulation; 
b) clinical and/or biochemical evidence of hyperan-
drogenism;
c) polycystic ovaries and exclusion of other endocri-
nopathies [6].
The Rotterdam definition is wider and includes many 
more patients; notably, patients without androgen excess are 
included whereas in the NIH 1990 definition androgen excess 
is a prerequisite [6]. 
PCOS is traditionally divided in Russian and ex-So-
viet scientific literature into “primary,” which manifests in 
puberty and is considered a separate nosological form, and 
“secondary,” which develops due to different endocrinopathies 
(adrenogenital, metabolic, Cushing’s syndrome etc.) [7].
Several metabolic abnormalities are characteristic of 
PCOS.  Impaired glucose tolerance, as evidence of insulin 
resistance, is present in about 31% to 35% of women with 
PCOS and can occur in both lean and obese women.  In 
contrast, insulin resistance occurs in about 8% of the general 
population [8].  Further, hyperinsulinemia resulting from 
insulin resistance perpetuates the development of PCOS. 
Insulin inhibits hepatic production of insulin-like growth 
factor binding protein-1 (IGFBP-1) and testosterone-binding 
globulin.  The free fraction of both IGFBP-1 and testosterone, 
therefore, will be increased, but this is only part of the cascade 
of events.  Insulin and IGFBP-1 both stimulate thecal androgen 
production; therefore, the net effect of hyperinsulinemia is 
higher androgen production in the ovary as well as a greater 
bioactive fraction of androgen [8].
Another key hormonal feature of PCOS is elevated lu-
teinizing hormone (LH) secretion from the pituitary and an 
increased ratio of LH to follicle-stimulating hormone (FSH). 
LH stimulates ovarian steroidogenesis, and an elevated LH-to-
FSH ratio will produce follicles that do not fully mature, but 
instead become numerous and cystic.  Immature follicles are 
deficient in aromatase, the enzyme that produces estrogen in 
the ovary by converting it from its precursor, testosterone.  In 
this manner, the PCOS ovarian follicle manufactures primarily 
androgens.  The abnormality is reinforced further by the con-
version of androgen to estrogen by aromatase in the periphery, 
which results in elevated circulating estrogens that feed back 
to the pituitary and disrupt normal LH secretion [7].
Among the variety of clinical manifestations and patho-
physiology of PCOS, the correlation to neurological disorders 
is an issue worthy of further investigation.  Most reports given 
in this regard have discussed an interrelation between PCOS 
and epilepsy, which is a serious health problem. 
PCOS and Epilepsy
The correlation between PCOS and epilepsy has been 
reported by many authors during recent decades [9].  Previous 
studies have described an association between epilepsy and 
features of the polycystic ovarian syndrome (PCOS) among 
women receiving treatment with antiepileptic drugs (AEDs), 
including valproic acid (VPA) [10].  This association with 
PCOS has been attributed to epilepsy itself by some investi-
gators [11], and to the use of VPA by others [10].
Table 1
Association between epilepsy and PCOS
Study No. No. (%) with PCOS
Odds 
ratio 95% CI P
Herzog et al., 1986 50 10 (20%) 3.4 1.2–9.1 0.01
Bilo et al., 1988 20 3 (15%) 2.4 0.4–10.1 0.18
Isojarvi et al., 1993 2381 3 (3.1%) 0.4 0.1–1.6 0.28
to to to
7 (7.1%)2 1.1 0.3–3.0 1.1
Bauer et al., 2000 93 6 (6.5%) 0.9 0.3–2.8 1.0
Bilo et al., 2001 50 13 (26%) 4.8 1.9–12.2 <0.001
Note: Odds ratios, 95% confidence intervals (95% CI), 
and two-sided Fisher’s exact test are used to compare 
prevalence of PCOS in each study with the maximum 
estimated community prevalence of 6.8% (13 of 192 women). 
1Ninety-eight women of 238 total subjects had complete 
evaluation for PCOS (31 VPA, 49 carbamazepine, 18 clonazepam, 
phenobarbital, clonazepam and/or carbamazepine). 
2The proportion with PCOS calculated from data available 
on 98 women for whom menstrual cycle irregularity (n 
= 47), hirsutism (n = 4), and menstrual irregularity with 
hyperandrogenemia (n = 3) was reported.  The range is 
reported because it is unclear whether women with hirsutism 
were the same as those with menstrual irregularity and 
hyperandrogenemia.
The percentage of women reported in each study to 
have PCOS varies widely because different researchers have 
used different definitions of the syndrome and have studied 
different groups.  Estimates range from as low as 3.1% to as 
high as 26% of all women in the studies (Table 1) [12, 13, 
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14, 15, 16].  This information is derived from a total of five 
clinical case series involving between 20 and 238 premeno-
pausal women receiving outpatient care in epilepsy centers 
in the United States [13], Italy [14, 16], Germany [15] and 
Finland [12].  In population-based studies, PCOS has been 
estimated to occur in 4.0–6.8% of premenopausal women 
[10, 11].  The prevalence of PCOS in epileptic populations 
was elevated in three of five studies when compared to the 
maximum predicted community prevalence of 6.8% (Table 
1) [13],[14] and significantly so in two studies, including the 
study by Bilo et al. [16].
Thus, reproductive endocrine disorders, such as PCOS, 
are common in women with epilepsy [10], however, there is 
uncertainty as to whether it is epilepsy or its treatment that 
predisposes them to PCOS.  Both epilepsy and antiepileptic 
drugs (AEDs) can have an effect on the feedback loop of the 
hypothalamic–pituitary–gonadal axis, which controls the 
synthesis and concentrations of sex hormones [17].
An examination of the reports, mentioned above, 
and other clinical series reveals significant disagreement 
among them in their conclusions about the association be-
tween epilepsy and PCOS. Several factors may explain the 
discrepancy in the findings.  The studies are all relatively 
small, permitting chance observations and selection bias 
to exert substantial effects.  The referral pattern for each 
of the epilepsy clinics in which studies were conducted 
may differ such that some may over-represent women with 
reproductive-endocrine disorders.  In addition, the type of 
epilepsy (generalized, focal), the location of seizure focus 
(temporal lobe, extra-temporal) and the responsiveness to 
therapy of study subjects varies among the clinical reports. 
Associations between PCOS and generalized epilepsy [13], 
temporal-lobe epilepsy [12], and no specific epilepsy type 
or seizure focus location [12, 16] have been reported. 
Moreover, the frequency of use of specific AEDs and the 
proportion of women receiving no treatment for their epi-
lepsy varies substantially among the clinical reports.  If an 
association of epilepsy with PCOS is mediated or caused 
by one or more AEDs, the number of subjects receiving 
that medication must be large enough to permit accurate 
analysis.  Finally, personal characteristics of study subjects 
that may modulate the relationship between epilepsy and 
PCOS—such as ethnicity and body weight—vary markedly 
among the clinical reports. 
In another study, the same group (Herzog et al.) found 
that there was a significant difference between the EEG 
laterality distributions associated with polycystic ovarian 
syndrome and those associated with hypogonadotrophic 
hypogonadism [18].  Patients with PCOS and untreated 
temporal lobe epilepsy had predominantly left-sided 
interictal epileptiform discharges in the EEG.  This dis-
tribution differed significantly from that of women with 
epilepsy who had no reproductive endocrine disorders. 
The fact that PCOS appears to be more frequent with 
left-sided than with right-sided unilateral temporal lobe 
epileptogenic discharges would also suggest that epilepsy 
induces PCOS [19].
Features of PCOS Associated with Valproate
An alternative explanation for the association between 
epilepsy and PCOS, is that PCOS is induced by use of VPA 
[19].  Several studies have been conducted in order to de-
termine the effects, if any, of AEDs on endocrine disorders. 
Scandinavian studies have suggested that there is a possible 
link between valproate and PCOS [12],[20],[21]; however, 
the impact of AEDs on endocrine disorders is debated.  In 
1993, Isojarvi et al. [12] reported the first association between 
valproate and cystic ovaries. The authors stated that nearly 
half of the 28 women treated with valproate monotherapy 
for epilepsy had amenorrhea, oligomenorrhea, or prolonged 
menstrual cycles, compared with 19% of the 120 women ta-
king Carbamazepine monotherapy. The presence of menstrual 
disturbances was associated with elevated free testosterone in 
women taking valproate alone or valproate plus Carbamaze-
pine.  Forty-three percent of women receiving valproate alone 
had PCOS, compared with 22% of women taking Carbamaze-
pine alone.  This study does not clearly differentiate between 
the possibility of an effect of valproate administration and the 
effects of epilepsy itself on menstrual disturbances or elevated 
free testosterone.  However, it is supportive of an association 
between valproate administration and cystic ovaries. In 1996, 
a second report from the same group demonstrated that 11 of 
22 obese women with epilepsy, taking valproate, had insulin 
resistance and elevated androgen levels [20].
The results of Isojärvi et al. have been widely publicised. 
However, they are not supported by the results of two recent 
studies [22],[23].  Bauer et al. [22] conducted a prospective 
study in 93 women with partial epilepsy in order to determine 
whether PCOS is a common finding in women treated with 
AEDs.  In this study the incidence of PCOS in patients treated 
with valproate monotherapy (11.1%) was similar to that for 
patients treated with Carbamazepine (10%) and also to that 
in patients receiving no medication (10.5%).  This suggests 
that the manifestation of PCOS in women with focal epi-
lepsy is not related to the administration of either valproate 
or Carbamazepine [22]. In another study investigating the 
effects of valproate, Phenobarbital and Carbamazepine on sex 
hormones and luteal function, Murialdo et al.[23] found that 
the prevalence of PCOS did not differ significantly between 
treatment groups.
The theory that VPA induced weight gain leads to 
increased insulin resistance with consequent hyperinsuline-
mia, and finally PCOS, does not explain why PCOS and/or 
hyperandrogenism was also high in lean VPA-treated patients. 
In an editorial comment on this study, Herzog [19] proposed 
that epilepsy may induce PCOS and that PCOS is treated by 
enzyme-inducing AEDs, but not by valproate, which is an 
enzyme-inhibiting AED.  By inducing hepatic enzymes that 
reduce biologically active testosterone in the serum and by 
increasing the binding and metabolism of testosterone, some 
AEDs may inadvertently treat hyperandrogenism and thus 
PCOS, while valproate therapy may not. SHBG is uniformly 
elevated by chronic treatment with Phenytoin, Carbamaze-
pine, Primidone and Phenobarbitone, but not with valproate 
[23].  Weight gain is a well-known side effect of valproate, 
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but it is not a primary diagnostic feature of PCOS.  Insulin 
resistance can be produced by weight gain itself; however, it 
is present as an independent endocrine dysfunction in both 
obese and lean women with PCOS.  It is unknown whether 
valproate is associated with insulin resistance in patients who 
do not gain weight while taking the drug.  Menstrual dysfunc-
tion and anovulation have been reported more frequently in 
women with epilepsy, but their association with valproate 
and epilepsy is mixed.  PCOS seems to be overrepresented 
in women with epilepsy and, in some reports, is specifically 
associated with valproate.  The clinical significance of this fact 
as an independent finding is unclear, but it is likely to at least 
be a harbinger of anovulation and subfertility.
PCOS and Other Neuropathies
In 2006, a case of thoracic myelopathy due to ossificati-
on of the posterior longitudinal ligament (OPLL) in a patient 
with policystic ovary syndrome was reported by authors from 
Japan [24].  A 24-year-old woman presented with a three-week 
history of muscle weakness and sensory disturbance in her 
bilateral lower extremities.  She also exhibited “moon-face,” 
hepertrichosis, obesity and hyperglycemia.  Myelography and 
computer tomography were performed, and OPLL was recog-
nized at levels T3 to T9 of the spine.  Hypercholesterolemia 
and abnormally high testosterone levels were found.  She also 
had polycystic lesions in both ovaries on magnetic resonance 
imaging, thus the diagnosis of polycystic ovary syndrome was 
established.  Her neurological symptoms worsened rapidly 
and she developed paraplegia.
The characteristic findings of obesity, insulin resistance 
with compensatory hyperinsulinemia, increased levels of free 
insulin-like growth factor-I (IGF-I) and hyperandrogenemia 
in patients with polycystic ovary syndrome were suspected to 
be related to the occurrence of OPLL.  The stature of female 
patients with OPLL in the thoracic spine corresponded to pa-
tients with polycystic ovary syndrome.  IGF-I was reported to 
be involved in the development of OPLL.  It was proposed that 
hormonal surveys for patients with OPLL in the thoracic spine 
might be useful for clarifying the pathogenesis of OPLL.
In 2007 a case of benign intracranial hypertension 
(pseudotumor cerebri), visual impairment, and hypothy-
roidism in association with polycystic ovary syndrome was 
reported in Austria [25].  A 20-year-old obese woman deve-
loped menstrual cycle irregularities beginning at 14 years of 
age, initially accompanied by bitemporal headache and later 
by diffuse headache, as well as bilateral visual impairment, 
described as sparkling black points.  Ophthalmologically there 
was a recurrent papilledema.  Clinical neurologic investigati-
ons revealed sore neck muscles.  Magnetic resonance imaging 
of the brain, orbita and cervical spine, and investigations of 
cerebrospinal fluid were non-informative.  Visually evoked 
potentials revealed demyelination of the optic nerves.  Gy-
necologic investigations revealed PCOS and endocrinologic 
investigations hypothyroidism and hyperandrogenism.  A 
possible relationship between pseudotumor cerebri and the 
ophthalmologic, gynecologic, and endocrinologic abnorma-
lities is discussed.
In 2008, a study was conducted by a group of specialists 
from Iran; the aim was to assess the prevalence and charac-
teristics of headache, especially migraine, in patients with 
PCOS compared with women without this disease [26].  One 
hundred thirty-three women with PCOS and 107 controls 
were interviewed by two neurologists experienced in headache 
diagnosis.  The headache disorders were classified according 
to the International Headache Society criteria.  Forty-five 
women (33.8%) of the 133 cases without PCOS complained of 
headache.  Of the PCOS patients, 48 women (44.9%) suffered 
from headache.  Thus migraine was not more frequent in wo-
men with PCOS.  It was concluded that male sex hormones, 
and especially testosterone, do not play an important role in 
the exacerbation of migraine headache.
In 2008, a case of multiple cerbral infarctions associ-
ated with polycystic ovaries and ovarian hyperstimulation 
syndrome (OHSS) was reported by a group of scientists from 
Korea [27].  A 31-year old woman was admitted with a chief 
complaint of left-sided motor weakness and motor aphasia. 
She had been diagnosed at an infertility clinic 6 months pre-
viously as having oligo-ovulation, infertility and polycystic 
ovaries.  Her medical history was unremarkable: no history 
of hypertension, migraine or obesity.  Induction of ovulation 
began 28 days prior to focal neurological symptoms.  The 
patient received oral clomiphene citrate (100 mg/day for 5 
days) and injections of human menopausal gonadotropin (75 
IU/day for 5 days). Two weeks later, oocytes were retrieved and 
eventually 6 embryos were transferred to her endometrium. 
Laboratory tests demonstrated that the serum white blo-
od cell count and levels of liver enzymes were elevated, while 
serum albumin was decreased.  Human chronic gonadotropin 
(hCG) was 8.3 mIU/ml (normal range at 2nd week after con-
ception: 0–400 mIU/ml); serum estradiol and progesterone 
levels increased up to 4,300 pg/ml (normal range during 1st 
trimester: 100–5,600 pg/ml) and 60.0 ng/ml (normal range 
during 1st trimester: 11.2–90.0 ng/ml), respectively.  Blood 
urea nitrogen, serum creatinine, prothrombin time, activated 
partial thromboplastin time, homocysteine and protein C 
were within normal limits.  Anticardiolipin antibody, lupus 
anticoagulant and activated protein C resistance were negative. 
MRI of the brain revealed an acute ischemic lesion on diffusi-
on-weighted and T 2 -weighted imaging in the territory of the 
right middle cerebral artery, but no occlusions of the major 
intracranial arteries and extracranial carotid and vertebral 
arteries were found on MR angiography.
The patient was started on intravenous heparin 
(21,600 U/day) to prevent further thromboembolic com-
plications; however, nystagmus and vomiting developed 
on day 3 after admission.  A repeated brain MRI showed 
newly developed left cerebellar infarction.  On hospital 
day 12, serum hCG was found elevated to 3,463 mIU/ml 
(normal range at 4th week after conception: 1,000–20,000 
mIU/ml), with subsequent abdominal ultrasonographic 
examination showing a triple pregnancy in the uterus. 
Therapeutic surgical abortion was performed on hospital 
day 21, and serum hCG, estrogen and progesterone levels 
returned to normal after the operation.
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The patient was placed on 100 mg/day aspirin pro-
phylaxis, and a follow-up examination at 6-months revealed 
residual, mild, left-arm weakness and motor aphasia.  It was 
concluded that the occurrence of progressive, multi-territorial 
infarctions, without atherosclerotic lesions in cerebral arteries 
visible on MRA and the absence of a cardioembolic source 
suggested that systemic conditions conducive to a hypercoa-
gulable state may have been responsible for cerebral infarction 
in this case.  It was speculated that sustained high levels of 
hCG due to triple pregnancy, combined with a prior history 
of polycystic ovaries, might have led to severe OHSS and 
subsequent cerebral infarction, despite anticoagulation treat-
ment.  In addition, hyperactivation of the hemostatic system 
likely played a role in the development of thromboembolism. 
Therefore, the alterations of hemostatic factors may also 
have contributed to the development of cerebral infarction. 
OHSS occurs more frequently and severely when combined 
with polycystic ovary syndrome [28, 29].  Although the exact 
mechanism of this phenomenon is not clearly defined, it may 
be related to the exaggerated response to gonadotropin in 
polycystic ovary syndrome.
Conclusions
PCOS has multiple etiologies; none is fully understood 
[10]. Its occurrence is under genetic influence as well as related 
to ovarian, hypothalamic, and glucose-modulating dysfunc-
tions.  In this light, it is difficult to state which is the specific 
reproductive dysfunction related to epilepsy.  
One explanation for the connection between PCOS and 
epilepsy: women whose seizures begin in the left temporal lobe 
may be more likely to have certain hormonal abnormalities 
that prevent ovarian follicles from maturing.  This leads to 
anovulation, the collection of cysts, and the release of more 
male hormones — all the criteria for a diagnosis of PCOS.
PCOS has another link to epilepsy: it may increase or 
worsen seizures.  The hormonal abnormalities related to 
anovulation include a lack of progesterone, which the ovaries 
usually produce in the days after ovulation.  Progesterone has 
antiseizure and mood-stabilizing properties.  The ovaries of 
women with PCOS, on the other hand, continue to produce 
estrogen, which promotes seizures and anxiety.
Theories underlying the occurrence of PCOS in epilepsy 
concern the mechanism of elevated LH.  Investigators specu-
late that epilepsy affects the brain in such a manner that it se-
condarily influences the reproductive system; by affecting the 
hypothalamic–pituitary axis (HPA), for example.  This hypo-
thesis was first proposed by Herzog et al. in 1986 but has been 
studied very little since then.  The sequence of events leading 
to elevated LH secretion begins as follows: seizure discharges, 
either ictal or interictal and involving medial temporal areas, 
stimulate the secretion of gonadotropin-releasing hormone 
(GnRH).  Next, increased GnRH pulse frequency promotes 
the secretion of LH at greater levels than the secretion of FSH, 
resulting in an elevated LH/FSH ratio [18].
Herzog et al. [19] studied LH pulse frequencies in wo-
men with epilepsy and found that the pulse frequency is incre-
ased with an especially marked increase in left temporal lobe 
epilepsy.  Furthermore, evidence for reproductive dysfunction 
in epilepsy based on a mechanism of HPA dysfunction has 
been reported.  Earlier-than-expected menopause has been 
described in women with high seizure rates - a finding that is 
also likely a manifestation of subtle HPA dysfunction, leading 
to early ovarian failure.  Therefore, the reproductive abnor-
malities in women of reproductive age with epilepsy (that is, 
ovulatory dysfunction and elevated circulating androgens,) 
which either look like or actually are PCOS, could be the result 
of seizures or interictal discharges affecting the HPA.
Mechanisms by which valproate can cause elevation 
of androgens and PCOS result from induction of androgen 
synthesis in the ovary, likely as a result of multiple proces-
ses.  One study using human, ovarian, thecal cell cultures 
showed that valproate induced ovarian androgen synthesis 
by augmenting transcription of steroidogenic genes [20]. 
Another report used ovarian follicles in culture with ovarian 
thecal and granulosal cells (so as to replicate an ovary,) and 
showed that valproate increased testosterone secretion from 
follicles but had differing effects based on the degree of LH 
stimulation in the culture and on maturity of the follicles. 
Further, valproate decreased the conversion of testosterone 
to estradiol, suggesting an inhibitory effect on the converting 
enzyme, aromatase [21].
Valproate produced ovarian cysts in nonepileptic Wistar 
rats at very high, supratherapeutic doses.  A study more appli-
cable to humans, however, evaluated the effects of valproate 
on nonepileptic, normally cycling female Rhesus monkeys. 
The monkeys were treated for 12 to 15 months, having achi-
eved therapeutic levels of valproate similar to those in seen 
in humans, and compared with control monkeys.  No effects 
on menstrual cycling (which normally is nearly identical to 
that in humans), ovulation, androgen levels, LH/FSH ratio, 
insulin response, or lipid profiles were found.  The ovaries, 
on pathologic evaluation, were normal as well.  These results 
suggest that the effects of valproate in women with epilepsy 
could be due to valproate exacerbating an already disturbed 
system, which is unable to compensate for its androgen-pro-
moting actions.
More information is needed about the use of valproate in 
women with epilepsy and its risk of inducing PCOS.  Common 
sense would dictate that, for a woman with epilepsy who has 
evidence of PCOS, the use of valproate should be judiciously 
considered.
Finally, it appears that PCOS occurs significantly more 
often in women with epilepsy than in others, especially among 
certain groups.  Studies using much larger groups will be nee-
ded for doctors to find out the details of how PCOS is related 
to the many types of epilepsy and seizure medicines.  The exact 
mechanisms of other reported cases of correlation between 
PCOS and neurological disorders are not clearly defined; it 
may be related to a dis-hormonal state in PCOS.
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